City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Leslie Popplewell, MD  
Search results:  6  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-6 Trials Jump to page:

COH Protocol Number: 16301 ClinicalTrials.gov Number: NCT02443077

Principal Investigator: Leslie Popplewell, MD
Sponsor: Cooperative Group

Title:  ALLIANCE A051301/BMT CTN 1201: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

COH Protocol Number: 16107 ClinicalTrials.gov Number: NCT01307267

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1 Study of PF-05082566 as a Single Agent in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma (NHL)

COH Protocol Number: 15310 ClinicalTrials.gov Number: NCT02260804

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma

COH Protocol Number: 15182 ClinicalTrials.gov Number: NCT02413489

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

COH Protocol Number: 14231 ClinicalTrials.gov Number: NCT02220842

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzamab in Patients with Relpased/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

COH Protocol Number: 13277 ClinicalTrials.gov Number: NCT02051257

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma

 
Results per page: 25 50 100 All 1-6 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.